公开(公告)号：US11702430B2

公开(公告)日：2023-07-18

申请号：US17040192

申请日：2019-03-28

申请人： Merck Sharp & Dohme LLC ,  Michael D. Altman ,  Brandon D. Cash ,  Jared N. Cumming ,  Duane E. DeMong ,  Andrew M. Haidle ,  James P. Jewell ,  Matthew A. Larsen ,  Min Lu ,  Ryan D. Otte ,  Brandon M. Taoka ,  Benjamin Wesley Trotter ,  Quang T. Truong

发明人： Michael D. Altman ,  Brandon D. Cash ,  Jared N. Cumming ,  Duane E. DeMong ,  Andrew M. Haidle ,  James P. Jewell ,  Matthew A. Larsen ,  Min Lu ,  Ryan D. Otte ,  Brandon M. Taoka ,  Benjamin Wesley Trotter ,  Quang T. Truong

IPC分类号： C07D513/04 ,  C07D495/04 ,  C07D277/64 ,  A61P37/04 ,  A61P35/00

CPC分类号： C07D513/04 ,  A61P37/04 ,  C07D495/04

摘要： Compounds of general formula (I), and their pharmaceutically acceptable salts, wherein R1, R2, R3, R5, R6, R8, R9, A, X1, X2, and X3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer.

公开(公告)号：US20210009608A1

公开(公告)日：2021-01-14

申请号：US17040192

申请日：2019-03-28

申请人： Michael D. ALTMAN ,  Brandon D. CASH ,  Jared N. CUMMING ,  Duane E. DEMONG ,  Andrew M. HAIDLE ,  James P. JEWELL ,  Matthew A. LARSEN ,  Min LU ,  Ryan D. OTTE ,  Brandon M. TAOKA ,  Benjamin Wesley TROTTER ,  Quang T, TRUONG ,  Merck Sharp & Dohme Corp.

发明人： Michael D. Altman ,  Brandon D. Cash ,  Jared N. Cumming ,  Duane E. DeMong ,  Andrew M. Haidle ,  James P. Jewell ,  Matthew A. Larsen ,  Min Lu ,  Ryan D. Otte ,  Brandon M. Taoka ,  Benjamin Wesley Trotter ,  Quang T. Truong

IPC分类号： C07D513/04 ,  C07D495/04 ,  A61P37/04

摘要： Compounds of general formula (I), and their pharmaceutically acceptable salts, wherein R1, R2, R3, R5, R6, R8, R9, A, X1, X2, and X3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer.

公开(公告)号：US20230183214A1

公开(公告)日：2023-06-15

申请号：US17920850

申请日：2021-05-04

申请人： Brandon D. CASH ,  Wenlang FU ,  George Madalin GIAMBASU ,  Andrew M. HAIDLE ,  Brett A. HOPKINS ,  Matthew A. LARSEN ,  Charles A. LESBURG ,  Ping LIU ,  Meredeth A. MCGOWAN ,  Qinglin PU ,  Sulagna SANYAL ,  Phieng SILIPHAIVANH ,  Catherine M. WHITE ,  Xin YAN ,  Merck Sharp & Dohme LLC

发明人： Brandon D. CASH ,  Wenlang FU ,  George Madalin GIAMBASU ,  Andrew M. HAIDLE ,  Brett A. HOPKINS ,  Matthew A. LARSEN ,  Charles A. LESBURG ,  Ping LIU ,  Meredeth A. MCGOWAN ,  Qinglin PU ,  Sulagna SANYAL ,  Phieng SILIPHAIVANH ,  Catherine M. WHITE ,  Xin YAN

IPC分类号： C07D403/10 ,  C07D413/10 ,  C07D409/06 ,  C07D235/26 ,  C07D403/06 ,  C07D419/10 ,  C07D401/14 ,  C07D401/06 ,  C07D409/14 ,  C07D405/06 ,  C07D401/12 ,  C07D401/08 ,  C07D495/04 ,  C07D417/10

CPC分类号： C07D403/10 ,  C07D235/26 ,  C07D401/06 ,  C07D401/08 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D405/06 ,  C07D409/06 ,  C07D409/14 ,  C07D413/10 ,  C07D417/10 ,  C07D419/10 ,  C07D495/04

摘要： Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases.